Internal Reference Number: FOI_9372
Date Request Received: 28/04/2026 00:00:00
Date Request Replied To: 12/05/2026 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Companies
| Question Number 1: Could you please provide the data for the last three months, i.e., January 2026 to March 2026. Over the past 3 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: 76 patients | |
| Question Number 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] ± Dexamethasone • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Daratumumab [Darzalex] monotherapy • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) • Lenalidomide [Revlimid] + Dexamethasone • Lenalidomide [Revlimid] monotherapy • Panobinostat + Bortezomib + Dexamethasone • Pomalidomide [Imnovid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] | |
| Answer To Question 2: • Belantamab Mafodotin [Blenrep] less than 5 • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone less than 5 • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0 • Bortezomib [Velcade] ± Dexamethasone 0 • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) 0 patients (see other for VCD) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0 • Carfilzomib [Kyprolis] + Dexamethasone 0 • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) less than 5 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 12 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 7 • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 10 • Daratumumab [Darzalex] monotherapy 0 • Elranatamab 6 • Idecabtagene vicleucel [Abecma] 0 • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 0 • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) 5 • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) 8 • Lenalidomide [Revlimid] + Dexamethasone less than 5 • Lenalidomide [Revlimid] monotherapy 29 • Panobinostat + Bortezomib + Dexamethasone less than 5 • Pomalidomide [Imnovid] + Dexamethasone 0 • Selinexor + Bortezomib [Velcade] + Dexamethasone 0 • Selinexor + Dexamethasone 0 • Talquetamab 0 • Teclistamab [Tecvayli] 0 • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] Less than 5 each for VCD (bortezomib/cyclophosphamide/dexamethasone), venetoclax, daratumumab/lenalidomide | |
| Question Number 3: In the last 3 months, how many patients have been initiated* on the following regimens? • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Lenalidomide [Revlimid] monotherapy • Lenalidomide [Revlimid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. | |
| Answer To Question 3: • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone less than 5 • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0 • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0 • Carfilzomib [Kyprolis] + Dexamethasone 0 • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 0 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 0 • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 0 • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 0 • Lenalidomide [Revlimid] monotherapy 0 • Lenalidomide [Revlimid] + Dexamethasone 0 • Selinexor + Bortezomib [Velcade] + Dexamethasone 0 • Selinexor + Dexamethasone 0 • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] less than 5 each for elranatamab and IRD *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. | |
| Question Number 4: In the last 3 months, how many patients have received the following second-line treatment? • Lenalidomide [Revlimid] + Dexamethasone | |
| Answer To Question 4: • Lenalidomide [Revlimid] + Dexamethasone 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at ÐÇ¿ÕÎÞÏÞ have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
